Equities

Glycorex Transplantation AB (publ)

Glycorex Transplantation AB (publ)

Actions
  • Price (EUR)0.1045
  • Today's Change0.003 / 2.96%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments143442
Total Receivables, Net4.905.683.77
Total Inventory6.334.853.52
Prepaid expenses1.041.351.13
Other current assets, total------
Total current assets264551
Property, plant & equipment, net171311
Goodwill, net------
Intangibles, net233840
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets6696102
LIABILITIES
Accounts payable1.542.991.13
Accrued expenses5.685.265.36
Notes payable/short-term debt000
Current portion long-term debt/capital leases4.404.333.85
Other current liabilities, total2.923.253.19
Total current liabilities151614
Total long term debt7.105.725.20
Total debt11109.05
Deferred income tax0.180.180.12
Minority interest------
Other liabilities, total------
Total liabilities222219
SHAREHOLDERS EQUITY
Common stock3.693.693.69
Additional paid-in capital120120120
Retained earnings (accumulated deficit)(79)(49)(40)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity447483
Total liabilities & shareholders' equity6696102
Total common shares outstanding747474
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.